MOLECULARMD provides innovative and reliable molecular diagnostics products and services to support clinical development, regulatory approval, and commercialization of targeted cancer therapies.

Using both gold-standard and innovative platforms, we design sensitive, specific, standardized assays that provide robust, reproducible results in an expeditious manner appropriate for decision-making by clinical investigators, sponsors, community physicians and patients.

At MolecularMD we are committed to accelerating the pace of targeted therapy development and personalizing medicine for cancer patients.

MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives

MolecularMD Announces Issuance of Patent Covering Methods for Therapeutic Resistance Monitoring in Lung Cancer Patients